MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ENSC Stock dropped -3.16% Today — RQD Quant Desk Flash
$0.44 -3.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.44
Ensysce Biosciences Inc. (ENSC) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $8.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.44 (-0.76%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-11.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENSC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY ENSC SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (34% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)
FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 40.2 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.53-1.9% Next Q
43
Q2 (-2Q)Grade D$0.52-9.6% Next Q
40
Q3 (-1Q)Grade E$0.47-6.4% Next Q
38
CurrentGrade D-$0.44-8.5% Hist 90D α
35
Trajectory: D (43) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ENSC Turnaround Squeeze
While ENSC currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.46) forces dealer call-delta covering toward $2.34.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENSC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ENSC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ENSC Stock dropped -3.16% Today — RQD Quant Desk Flash
Ensysce Biosciences Inc. (ENSC) dropped -3.16% to $0.44, trading at 11% of its 52-week range ($0.23 – $2.23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 11% of its 52-week range ($0.23 – $2.23) with RSI-14 at 40.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ENSC Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENSC)
- ✓Walkthrough of ENSC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ENSC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.92%🛡️ HOLDING TREND SUPPORT
2026-10-30O $0.44H $0.44L $0.42C $0.44VOL 108.5K
RES: $0.64SUP: $0.43SMA50: $0.45SMA200: $0.43
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ENSC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ENSC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ENSC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENSC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENSC)
Health Care Rank #830 of 1016
⚔️ CMMB vs ENSC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ENSC vs. CMMB, PTN, INM, SNGX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Ensysce Biosciences Inc. (ENSC) ranks #830 by composite RQD confidence (35/100, grade D-) and #908 by equity capitalization ($8.5M). Within this direct 5-issuer industry benchmark cohort, ENSC leads on earnings valuation at N/A trailing P/E, while ENSC leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ENSC at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ENSC
ACTIVE
Ensysce Biosciences Inc. | D- | 35/100 | — | — | -35.0% | -3.16% | $8.5M | Benchmark Subject |
| CMMB Chemomab Therapeutics Ltd. | D- | 38/100 | — | — | -35.0% | -0.91% | $8.8M | /cmmb-vs-ensc → |
| PTN Palatin Technologies Inc. | D- | 38/100 | — | — | -35.0% | -3.33% | $8.8M | /ptn-vs-ensc → |
| INM InMed Pharmaceuticals Inc. | D | 47/100 | — | 34.5% | -35.0% | +1.61% | $8.9M | /inm-vs-ensc → |
| SNGX Soligenix Inc. | D | 44/100 | — | — | -35.0% | -1.55% | $8.0M | /sngx-vs-ensc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001716947In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ensysce Biosciences Inc. (ENSC) reported GAAP revenue of $5.1M (-2.8% vs. FY2024 revenue of $5.2M , and +127.2% cumulative change since FY2023) , GAAP net income of -$10.2M, operating cash flow of -$7.8M, and free cash flow of -$7.9M (-5.7% YoY). On the balance sheet, ENSC closed FY2025 with $7.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $5.1M | -$10.2M | -$7.8M | -$7.9M | $7.5M | — |
| FY2024 (FY) | 2024-12-31 | $5.2M | -$8.0M | -$7.5M | -$7.5M | $5.6M | — |
| FY2023 (FY) | 2023-12-31 | $2.2M | -$10.6M | -$10.8M | -$10.8M | — | — |
3. ENSC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ENSC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Ensysce Biosciences Inc. (NASDAQ: ENSC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.44 (-3.16% 1D, market cap $8.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ENSC ranks #830 in composite RQD confidence.
How does ENSC compare to CMMB and PTN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENSC carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CMMB (Chemomab Therapeutics Ltd.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M) and PTN (Palatin Technologies Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $8.8M). Among the 5-stock peer group, ENSC leads on earnings multiple (N/A) while ENSC leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ENSC?
Per ENSC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001716947), Ensysce Biosciences Inc. generated $5.1M in revenue (-2.8% YoY), -$10.2M in net income, and -$7.9M in free cash flow against $7.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ENSC trading relative to its 50-day, 200-day, and 52-week technical levels?
ENSC last traded at $0.44 (-3.16% on volume of 177,469 shares), positioning the stock -2.22% below its 50-day simple moving average ($0.45) and +2.33% above its 200-day simple moving average ($0.43). Across its 52-week range of $0.23 to $2.23, ENSC sits at the 10.5% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.50).
ENSC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ENSC stock moving today?
Why ENSC Stock dropped -3.16% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.